Schmutzler C, Brtko J, Bienert K, Köhrle J
Klinische Forschergruppe, University of Würzburg, Germany.
Exp Clin Endocrinol Diabetes. 1996;104 Suppl 4:16-9. doi: 10.1055/s-0029-1211693.
Retinoic acids (RAs), well characterized regulators of proliferation and differentiation, partly re-differentiate follicular thyroid carcinoma cell lines (FTC-133, FTC-238, and HTC-TSHr) as well as SV40-transfected immortalized thyroid cell lines (ori3 and 7751). This is indicated by the stimulation of type I 5'-deiodinase and other differentiation markers. As demonstrated by RT-PCR, electrophoretic mobility shift, and [3H]-retinoic acid binding assays, thyroid carcinoma cell lines express RA receptor mRNAs and functional ligand- and DNA-binding receptor proteins able to mediate RA-dependent signal transduction. Together, these properties make these thyroid-derived cell lines useful in vitro models for studying the effects of an RA re-differentiation therapy of thyroid cancer.
维甲酸（RAs）是已被充分表征的增殖和分化调节剂，它能使滤泡状甲状腺癌细胞系（FTC - 133、FTC - 238和HTC - TSHr）以及SV40转染的永生化甲状腺细胞系（ori3和7751）部分重新分化。这一点通过I型5'-脱碘酶和其他分化标志物的刺激得以体现。如逆转录聚合酶链反应（RT-PCR）、电泳迁移率变动分析以及[3H] - 维甲酸结合试验所证明的，甲状腺癌细胞系表达维甲酸受体mRNA以及能够介导维甲酸依赖性信号转导的功能性配体结合和DNA结合受体蛋白。这些特性共同使得这些源自甲状腺的细胞系成为研究维甲酸对甲状腺癌再分化治疗效果的有用体外模型。
